摘要
肾细胞癌是泌尿系常见的恶性肿瘤,目前主要的治疗手段是手术和靶向治疗。近年来,免疫治疗逐渐成为肾细胞癌治疗领域的研究热点。免疫检查点抑制剂能够通过阻断其通路促进肿瘤特异性T细胞的活化,达到内源性强化抗肿瘤免疫反应。同时,相关临床试验表明免疫检查点抑制剂联合抗血管生成药物可以给晚期肾细胞癌患者带来更多的临床获益。然而,新的免疫治疗方法在临床应用中也面临诸多挑战。该文综述了几种常见的免疫检查点抑制剂及免疫联合治疗肾细胞癌的研究进展。
Renal cell carcinoma(RCC)is a common malignant tumor of urinary system.At present,the main treatment for RCC are operation and targeted therapy.In recent years,immunotherapy has gradually become a research hotspot in the therapy for RCC.Immune checkpoint inhibitors can promote the activation of tumor-specific T cells by blocking the immune checkpoint pathway and enhance the endogenous anti-tumor immune response.At the same time,relevant clinical trials have shown that immune checkpoint inhibitors in combination with antiangiogenic agents can bring more clinical benefits to patients with advanced renal cell carcinoma.However,new immunotherapy methods also face many challenges in clinical application.This paper briefly reviews the advance in several common immune checkpoint inhibitors and immune combination therapy in renal cell carcinoma.
作者
敖智宪
柳建军
莫介荣
陈立新
AO Zhi-xian;LIU Jian-jun;MO Jie-rong;CHEN Li-xin(Department of Urology,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524023,China)
出处
《广东医科大学学报》
2020年第2期134-137,共4页
Journal of Guangdong Medical University
关键词
肾细胞癌
免疫检查点抑制剂
程序性死亡-1
免疫联合治疗
renal cell carcinoma
immune checkpoint inhibitors
programmed death-1
immune combination therapy
